ORDERING AGREEMENT between LONZA SALES AG and ELUSYS THERAPEUTICS, INC.Ordering Agreement • March 31st, 2023 • NightHawk Biosciences, Inc. • Pharmaceutical preparations • Delaware
The terms stated in this Agreement (“the Agreement”) apply to orders by Elusys Therapeutics, Inc., located at 25 Riverside Drive, Unit 1, Pine Brook, New Jersey 07058 (hereinafter referred to as “Elusys”, “Contractor” or “Elusys”) to Lonza Sales AG, a Swiss corporation, with its principal office at Muenchensteinerstrasse 38, CH- 4002 Basel, Switzerland, (hereinafter referred to as “Subcontractor” or “Lonza”). Specifically, this Agreement shall govern orders of Bulk Drug Substance (“BDS”) of Elusys’ proprietary molecule designated ETI-204 (“Anthim”), which shall be manufactured in accordance with the current Good Manufacturing Practice (“cGMP”) Regulations (21 C.F.R, §§ 210.1-211.208) and shall be manufactured at Lonza Portsmouth’s Facility in Portsmouth, NH, USA.
AMENDMENT NO. 79 to the BULK DRUG SUBSTANCE ORDERING AGREEMENT EFFECTIVE 5 FEBRUARY 2015 between LONZA SALES AG and ELUSYS THERAPEUTICS, INC.NightHawk Biosciences, Inc. • March 31st, 2023 • Pharmaceutical preparations
IN WITNESS WHEREOF, the parties have caused this Amendment No. 79 to be executed by their representatives thereunto duly authorised as of the day and year first written.
